The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
about
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataAnnual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From ChinaUsing NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms.Why We Should Be Willing to Pay for Hepatitis C Treatment.Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.Hepatitis C Virus-Induced Monocyte Differentiation Into Polarized M2 Macrophages Promotes Stellate Cell Activation via TGF-βHCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Global Elimination of Hepatitis C Virus.Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.Hepatitis C-A clinical review.The impact of hepatitis C virus outside the liver: Evidence from Asia.Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702.The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.An Electronic Health Record-based Intervention to Promote Hepatitis C Virus Testing Among Adults Born Between 1945 and 1965: A Cluster-randomized Trial.Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.Circulating and Exosome-Packaged Hepatitis C Single-Stranded RNA Induce Monocyte Differentiation via TLR7/8 to Polarized Macrophages and Fibrocytes.Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
P2860
Q26777506-1CEE6C24-341B-4430-9FEE-C53257BE5251Q28072257-A6925D9E-5729-4C93-B2C6-41C5AE60B23CQ28550101-CEE86D15-91D9-4E18-9537-C682627F05D2Q30746254-E8654970-15ED-4B98-A464-283609491E3FQ33629561-967A3EB4-0E58-46CF-B557-53662F464B5CQ35942041-B6BADE54-DC9B-4E99-BFE4-D04F034A9996Q35994877-93572067-C219-4B8E-97A4-77F983A3D54CQ36075161-2C386ADD-AD4F-4185-8518-31262628779CQ36663835-402E06F2-8D9E-4D21-B1BB-7CD083AA9712Q36783211-DD847861-76A0-4F72-B9B6-B9C0A11BDE25Q37018340-DA56C886-2EA1-4104-8A07-62426516E71DQ37296716-C9B19770-9B7D-419C-95D0-30635B20125FQ37368417-E93AAE73-80F6-41EE-8F8A-BE5AAA053F8DQ37421533-9BC577F9-BCB6-4F52-BCAB-C417569F1CF4Q37578288-5FE0B252-9D84-4FA8-805E-DF894E658847Q37735774-124EE8D1-2430-4C5B-8C63-33C6AB53A8BBQ38405059-17537445-F772-4AD1-87D3-E12CF2BA5AD7Q38635796-39CD3337-1FB4-4011-9B66-2F0306FE7BFDQ38642932-DC9389B5-8165-4324-A8DC-EE336BEDD2A3Q38691333-261C7B50-7A0A-4B2B-8E61-8FCFE940B61BQ38763789-5F29C630-F8CF-4F22-B85F-5CD25A0B041DQ38812892-15D20DF8-C078-4990-975E-4AB029B93F6EQ38982462-D5A366EB-0288-4384-8126-489929EE37BEQ39043108-C6691868-260E-4931-9D2D-1A35C414FCF9Q39102936-AC1C7CE2-697A-496D-8A55-6320234072A2Q39506797-1BCB9508-112F-4648-AE66-3ADC6123F953Q40064478-234F0FF4-E857-4C1C-AF51-80D5ECC3AD36Q40078226-2D414B01-5158-4221-B7A9-34B1FED13708Q40119164-F4A2962D-446F-4752-8E97-68C1751074F4Q40119169-F7D06E55-47C0-4E5B-855B-F69545C31B4EQ40168920-BDAFF0F2-A8C4-414F-8229-9245D5CA94E9Q40197476-01B087CD-57E2-44D8-A96B-9BAA9063FDE8Q40294951-2F26D646-9A95-45D4-BC76-636605C514F4Q40338014-3A0F3225-26A9-46B5-BDEC-304AB6F6E190Q40358165-5C56A882-BF44-466B-A6B3-59839604A3FFQ40524477-E7C89E5F-6C6D-48C4-885A-92B1638A6CE2Q40637339-63DFAA5B-C85B-40BE-B448-E86886855987Q40878993-D8A4C253-4E2B-472E-8C46-A9A332328044Q41043367-C4E1C913-80F3-4062-A317-CE2F147531B6Q41056478-6F813D2A-89DE-4A5D-ABB9-85BAED703FB6
P2860
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The cost-effectiveness, health ...... atments for hepatitis C virus.
@en
type
label
The cost-effectiveness, health ...... atments for hepatitis C virus.
@en
prefLabel
The cost-effectiveness, health ...... atments for hepatitis C virus.
@en
P2093
P2860
P356
P1476
The cost-effectiveness, health ...... atments for hepatitis C virus.
@en
P2093
Bryce D Smith
Danielle K Liffmann
David B Rein
John S Wittenborn
John W Ward
P2860
P304
P356
10.1093/CID/CIV220
P407
P577
2015-03-16T00:00:00Z